Irinotecan binds to the internal cavity of beta-lactoglobulin: A multi-spectroscopic and computational investigation

N Bijari1, S Ghobadi1, K Derakhshandeh2

  • 1Department of Biology, Faculty of Science, Razi University, 67149-67346, Kermanshah, Iran.

The binding of irinotecan, a potent anti cancer drug, to bovine beta-lactoglobulin (β-LG) was investigated by various spectroscopic techniques including fluorimetry, circular dichroism (CD), UV-vis, and Fourier transform infrared (FT-IR), in 10mM phosphate buffer, pH 7.75, in combination with a molecular docking study. Analysis of the fluorescence quenching data showed that combined static and dynamic quenching occurs, with the predominant contribution of the static mode. Molecular docking results were in full agreement with the results obtained from thermodynamic analysis of the fluorescence data indicating the existence of one binding site for irinotecan in β-LG structure and revealed the hydrophobic nature of the interaction between irinotecan and the protein. The binding distance between β-LG and irinotecan, r, was estimated to be 5.74nm based on the Förster's theory of non-radiative energy transfer. The obtained results of near-UV CD and FT-IR experiments suggested the occurrence of partial compactness of the protein structure upon irinotecan binding. Based on the experimental data and the possible binding mode revealed by molecular docking study, we concluded that irinotecan binds to the hydrophobic calyx of β-LG with induction of some alterations in the secondary and tertiary structure of the protein.

Related Concept Videos

Drug Binding to Blood Components01:30

Drug Binding to Blood Components

When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
598
Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
4.4K
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
4.3K
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
567